Clinical Research Directory
Browse clinical research sites, groups, and studies.
Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
Sponsor: Novartis Pharmaceuticals
Summary
This study is a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC. An observational study design, without a strict, mandated visit schedule or mandated treatment regimen was chosen as the most appropriate to collect available data in a real life setting. For that reason, this NIS does not impose a therapy protocol, diagnostic/therapeutic procedure or a visit schedule. The diagnostic or monitoring procedures are only those ordinarily applied to the therapeutic strategy and to routine clinical care and will take place as per investigator's discretion. This includes e.g. visit frequency, injection frequency and types of assessments performed - only data from routine medical practice will be collected as part of the study.
Official title: OBservationaL stUdy to Evaluate Fluid reSolution and Effectiveness in Patients Receiving Beovu (Brolucizumab) Under KeY Treatment Schemes in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
OBSERVATIONAL
Enrollment
572
Start Date
2020-11-05
Completion Date
2025-11-17
Last Updated
2026-07-29
Healthy Volunteers
No
Interventions
brolucizumab
There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
Locations (41)
Novartis Investigative Site
Munich, Bavaria, Germany
Novartis Investigative Site
Neuburg A.d. Donau, Bavaria, Germany
Novartis Investigative Site
Würzburg, Bavaria, Germany
Novartis Investigative Site
Würzburg, Bavaria, Germany
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Novartis Investigative Site
Göttingen, Lower Saxony, Germany
Novartis Investigative Site
Osnabrück, Lower Saxony, Germany
Novartis Investigative Site
Rostock, Mecklenburg-Vorpommern, Germany
Novartis Investigative Site
Trier, Rhineland-Palatinate, Germany
Novartis Investigative Site
Saarbrücken, Saarland, Germany
Novartis Investigative Site
Dresden, Saxony, Germany
Novartis Investigative Site
Leipzig, Saxony, Germany
Novartis Investigative Site
Schneeberg, Saxony, Germany
Novartis Investigative Site
Halle, Saxony-Anhalt, Germany
Novartis Investigative Site
Jena, Thuringia, Germany
Novartis Investigative Site
Aschersleben, Germany
Novartis Investigative Site
Bayreuth, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Bonn, Germany
Novartis Investigative Site
Breisach, Germany
Novartis Investigative Site
Chemnitz, Germany
Novartis Investigative Site
Cologne, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Esslingen am Neckar, Germany
Novartis Investigative Site
Glauchau, Germany
Novartis Investigative Site
Homburg, Germany
Novartis Investigative Site
Hösbach, Germany
Novartis Investigative Site
Kiel, Germany
Novartis Investigative Site
Leipzig, Germany
Novartis Investigative Site
Magdeburg, Germany
Novartis Investigative Site
Marienberg, Germany
Novartis Investigative Site
Münster, Germany
Novartis Investigative Site
Neubrandenburg, Germany
Novartis Investigative Site
Schönebeck, Germany
Novartis Investigative Site
Stralsund, Germany
Novartis Investigative Site
Sulzbach, Germany
Novartis Investigative Site
Torgau, Germany
Novartis Investigative Site
Waren, Germany
Novartis Investigative Site
Würzburg, Germany